Hologic (HOLX) announced that the FDA has granted 510(k) clearance for the company’s Aptima SARS-CoV-2 assay, which was first granted Emergency Use Authorization status in May 2020.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic’s Earnings Call: Mixed Outlook Amidst Growth and Challenges
- Hologic price target lowered to $85 from $88 at RBC Capital
- Reddit initiated, Cigna downgraded: Wall Street’s top analyst calls
- Hologic price target lowered to $90 from $95 at Raymond James
- Hologic downgraded to Market Perform from Outperform at Leerink